Coya Therapeutics, Inc. (COYA): Average Forecast Price
This daily price chart for Coya Therapeutics, Inc. (COYA) reflects market expectations, with the current indicator standing at 15.25. The business relies on contract manufacturing of drugs, focusing on patents and research. Coya Therapeutics, Inc. (COYA) is implementing advanced methods to combat inflammation during brain degeneration. Thanks to its first-mover status in ALS treatment, the brand enjoys exceptional authority within the scientific community.
Analytical breakdowns for Coya Therapeutics, Inc. (COYA)
- market price and analyst price targets:
- stock exchange capitalization data:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Equity Ratio Coya Therapeutics, Inc.|COYA - Long-Term Debt to Capital|Current Liabilities to Capital coyatherapeutics.com|COYA - Company Total Debt|Debts to Book Capitalization Coya|COYA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Coya Therapeutics|Immediate Liquidity coyatherapeutics.com
- earnings and multiples data:
COYA - Net Profit|Future Profit Coya Therapeutics, Inc.|COYA - Price to Earnings Ratio|Projected Price to Earnings Ratio coyatherapeutics.com|COYA - Price/Earnings to Growth Multiple|Company Value to EBITDA Coya|COYA - Operating profit EBITDA|Net earnings per share (EPS TTM) Coya Therapeutics|COYA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months coyatherapeutics.com|COYA - Net earnings per share growth this year|Projected earnings per share increase next year Coya Therapeutics, Inc.
- issuer revenue and sales details:
Summary company analytics:COYA Coya Therapeutics Inc
The high scalability of Coya Therapeutics, Inc. (COYA) neurodegenerative disease therapies enables global product replication, rendering the average forecast benchmark from investment banks a key indicator of market recognition for its intellectual capital. This chart aggregates target prices from leading analysts, smoothing out market noise to identify a reversal in professional expectations, which helps investors determine the asset's fair value while avoiding debt load traps.
Competitors of Coya Therapeutics, Inc.
Consensus Target biogen.com BIIB|Price Target Chart Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd (RGC) - Average Forecast Price|AXSM: Consensus Target|Average Forecast Price ACADIA Corp|XENE: Analyst Consensus Forecast|vikingtherapeutics.com (VKTX) - Analyst Consensus Forecast|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Analyst Consensus Forecast|Consensus Target Alector Therapeutics (ALEC)|Price Target Chart Annexon (ANNX)|OMER - Average Forecast Price|Neurogene Corp - Consensus Target|AC Immune Inc (ACIU) - Average Forecast Price|Voyager Therapeutics - Analyst Consensus Forecast|NMRA - Analyst Consensus Forecast|SCLX (Scilex) - Consensus Target|Tevogen Bio Holdings Inc. - Fair Value Consensus|Consensus Target ACOG|CGTX (cogrx.com) - Analyst Forecast Prices|Analyst Consensus Forecast IKT|SAVA (cassavasciences.com) - Fair Value Consensus|Analyst Consensus Forecast ASRT (Assertio)|VistaGen Therapeutics, Inc. (VTGN) - Average Forecast Price|OVID - Price Target Chart|Fair Value Consensus ABOS (Acumen Pharmaceuticals, Inc)|CRVO: Analyst Consensus Forecast|Alterity Therapeutics Limited (ATHE) - Analyst Consensus Forecast|Price Target Chart Clene Inc|PepGen Corp - Forecast Levels Chart|Analyst Consensus Forecast JUNS|RLMD - Average Forecast Price|Annovis Bio, Inc. - Consensus Target|Analyst Consensus Forecast Grace Therapeutics Inc GRCE|AIFF: Consensus Target|Klotho Neurosciences Inc - Analyst Forecast Prices|NRSN: Analyst Consensus Forecast|RVPH - Analyst Median Target|MTVA (MetaVia Inc.) - Analyst Consensus Forecast|Consensus Target neuraxis.com (NRXS)|Price Target Chart Helius Medical (HSDT)|Analyst Median Target passagebio.com|Neuphoria Therapeutics - Consensus Target|Fair Value Consensus NERV|Athira Pharma, Inc. - Analyst Consensus Forecast|Analyst Median Target addextherapeutics.com ADXN|alzamend.com (ALZN) - Price Target Chart|Broker Consensus Forecast CYCN|PTIX (Protagenic Therapeutics Inc.) - Analyst Consensus Forecast|Consensus Target Pasithea (KTTA)|Consensus Target CRGT (Cortigent, Inc.)|Analyst Median Target avenuetx.com|Analyst Consensus Forecast BCLI (BrainStorm Cell Therapeutics)|CARA - Consensus Target|CHRO - Price Target Chart|Average Forecast Price Eliem Therapeutics|ITCI (intracellulartherapies.com) - Consensus Target|Average Forecast Price longboardpharma.com (LBPH)|MRNS (Marinus Pharmaceuticals, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast NKGen Biotech Inc|Price Target Chart NeuroBo (NRBO)|Sage Therapeutics Inc - Broker Consensus Forecast|Analyst Consensus Forecast SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Average Forecast Price|VIGL: Consensus Target|WENA - Analyst Consensus Forecast|Cerevel (CERE) - Price Target Chart
